The expression of C2 showed a trend of upregulation during nivolumab treatment, whereas C2 exhibited no significant changes or even partial downregulation in the immunotherapy failure group ( Figure 1 A).
← all excerpts
Tumoral C2 Regulates the Tumor Microenvironment by Increasing the Ratio of M1/M2 Macrophages and Tertiary Lymphoid Structures to Improve Prognosis in Melanoma.
1
—
—